Press Releases

  • Dec 8, 2017
    EMERYVILLE, Calif. , Dec. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted 64 new employees the option to purchase an aggregate of 77,550 shares of the company’s common stock, at a per
  • Nov 22, 2017
    EMERYVILLE, Calif. , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences: Richard A. King , the company's Chief Operating Officer, is scheduled to present at the 29th Annual
  • Nov 8, 2017
    EMERYVILLE, Calif. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option to purchase an aggregate of 15,300 shares of the company's common stock, at a
  • Nov 2, 2017
    EMERYVILLE, Calif. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30, 2017 . "We are thrilled that GOCOVRI (amantadine) extended release capsules is approved for
  • Oct 26, 2017
    EMERYVILLE, Calif. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report third quarter 2017 financial results on Thursday, November 2, 2017 after market close. Subsequently, Adamas' management team will host a conference call and
  • Oct 25, 2017
    EMERYVILLE, Calif. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Drug Products (OOPD) has recognized by letter to the company the seven-years of orphan drug exclusivity for GOCOVRI
  • Oct 11, 2017
    EMERYVILLE, Calif. , Oct. 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Mardi C. Dier , Chief Financial Officer of Portola Pharmaceuticals, Inc., to its Board of Directors. Ms. Dier will serve on the Audit Committee. Ms.
  • Oct 6, 2017
    EMERYVILLE, Calif. , Oct. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted eleven new employees the option to purchase an aggregate of 78,750 shares of the company's common stock, at a
  • Sep 13, 2017
    EMERYVILLE, Calif. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from 8:00 a.m. - 11:00 a.m. ET in New York, NY . The event will be hosted by members of the Adamas
  • Sep 11, 2017
    EMERYVILLE, Calif. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees the option to purchase an aggregate of 15,450 shares of the company's common